News | January 08, 2026
Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Subscribe To Our Newsletter & Stay Updated
